These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8422814)

  • 1. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators.
    Vinik AI; Colwell JA
    Diabetes Care; 1993 Jan; 16(1):37-44. PubMed ID: 8422814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
    Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
    Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
    Lahdenperä S; Tilly-Kiesi M; Vuorinen-Markkola H; Kuusi T; Taskinen MR
    Diabetes Care; 1993 Apr; 16(4):584-92. PubMed ID: 8462384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE; Shapiro DR; Tate AC; Goldberg RB; Stein EA
    Clin Ther; 1995; 17(2):186-203. PubMed ID: 7614520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
    Bell DS
    Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
    Avogaro A; Piliego T; Catapano A; Miola M; Tiengo A
    Acta Diabetol; 1999 Jun; 36(1-2):27-33. PubMed ID: 10436249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
    Fasching P; Rohac M; Liener K; Schneider B; Nowotny P; Waldhäusl W
    Horm Metab Res; 1996 May; 28(5):230-6. PubMed ID: 8738112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
    Schweitzer M; Tessier D; Vlahos WD; Leiter L; Collet JP; McQueen MJ; Harvey L; Alaupovic P
    Atherosclerosis; 2002 May; 162(1):201-10. PubMed ID: 11947915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
    Goldberg R; La Belle P; Zupkis R; Ronca P
    Am J Cardiol; 1990 Sep; 66(8):16B-21B. PubMed ID: 2206032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
    Skillman CA; Raskin P
    Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
    Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
    Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.
    Krempf M; Berthezène F; Wemeau JL; Moinade S; Desriac I; Amelineau E; Passa P
    Diabetes Metab; 1997 Apr; 23(2):131-6. PubMed ID: 9137901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.